Experience with Octreotide in patients with castration refractory prostate cancer

被引：0
|
作者：
Ganov, D. I. [1 ]
Varlamov, S. A. [1 ]
机构：
[1] Altai State Med Univ, Kussian Acad Med Sci, NN Blokhin Russian Canc Res Ctr, Altai Branch, Barnaul, Russia
来源：
ONKOUROLOGIYA | 2011年 / 7卷 / 04期
关键词：
castration refractory prostate cancer; sustained-release octreotide;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fifteen patients with castration refractory prostate cancer have been treated with sustained-release octreotide in combination with dexamethasone at the Altai Territory Oncology Dispensary since 2008. Control PSA test revealed that 9 (60 %) patients had positive changes; tumor process stabilization was noted in 4 (26.7 %) and only 2 (13.3 %) were found to have disease progression. Thus, more than 86 % of patients responded to combination treatment with sustained-release octreotide + dexamethasone. Octreotide treatment caused no serious specific adverse toxic reactions.
引用
收藏
页码：71 / 73
页数：3
相关论文
共 50 条
  • [31] Metronomic Cyclophosphamide and Dexamethasone is Active in Docetaxel, Castration Refractory, Prostate Cancer
    Peel, D.
    Sundar, S.
    CLINICAL ONCOLOGY, 2009, 21 (10) : 801 - 801
  • [32] Recent Advances in the Treatment for Metastatic Castration-Refractory Prostate Cancer
    Kwong, P. W. K.
    HONG KONG JOURNAL OF RADIOLOGY, 2013, 16 (04): : S44 - S49
  • [33] Predictive Factors for Response to Abiraterone in Metastatic Castration Refractory Prostate Cancer
    Afshar, Mehran
    Al-Alloosh, Fawaz
    Pirrie, Sarah
    Rowan, Clare
    James, Nicholas D.
    Porfiri, Emilio
    ANTICANCER RESEARCH, 2015, 35 (02) : 1057 - 1063
  • [34] Modular therapy approach in metastatic castration-refractory prostate cancer
    Walter, B.
    Rogenhofer, S.
    Vogelhuber, M.
    Berand, A.
    Wieland, W. F.
    Andreesen, R.
    Reichle, A.
    WORLD JOURNAL OF UROLOGY, 2010, 28 (06) : 745 - 750
  • [35] Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan
    Akakura, Koichiro
    Uemura, Hiroji
    Kawakami, Satoru
    Yokomizo, Akira
    Nakamura, Motonobu
    Nishimura, Kazuo
    Komori, Tetsushi
    Ledesma, Dianne Athene
    FUTURE ONCOLOGY, 2024, 20 (12) : 781 - 798
  • [36] OCTREOTIDE AND BROMOCRIPTINE IN PATIENTS WITH STAGE D2 PROSTATE-CANCER WHO RELAPSED DURING TREATMENT WITH FLUTAMIDE AND CASTRATION
    DUPONT, A
    BOUCHER, H
    CUSAN, L
    LACOURCIERE, Y
    EMOND, J
    LABRIE, F
    EUROPEAN JOURNAL OF CANCER, 1990, 26 (06) : 770 - 771
  • [37] The First Experience on Lutetium (lu)-177 Prostate Specific Antigen (PSMA) Treatment in Castration Resistant Prostate Cancer Patients
    Soydal, C.
    Ozkan, E.
    Nak, D.
    Kucuk, O. N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S415 - S415
  • [38] Second-Line Therapy in metastatic castration refractory Prostate Cancer (mCRPC)
    Rexer, H.
    Graefen, M.
    Merseburger, A.
    UROLOGE, 2019, 58 (03): : 359 - 360
  • [39] Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer
    Berghen, Charlien
    Joniau, Steven
    Ost, Piet
    Poels, Kenneth
    Everaerts, Wouter
    Decaestecker, Karel
    Haustermans, Karin
    Devos, Gaetan
    De Meerleer, Gert
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (02): : 305 - 309
  • [40] Efficacy of low-dose dexamethasone in castration-refractory prostate cancer
    Venkitaraman, Ramachandran
    Thomas, Karen
    Huddart, Robert A.
    Horwich, Alan
    Dearnaley, David P.
    Parker, Chris C.
    BJU INTERNATIONAL, 2008, 101 (04) : 440 - 443
12345